Buscar resultados de ensayos clínicos
Hyperparathyroidism, Secondary - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism Condición: Secondary Hyperparathyroidism Fecha: 2010-12-03 Intervenciones:
|
Completed |
Nombre del estudio: Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) Condición: Secondary Hyperparathyroidism Fecha: 2009-01-22 Intervenciones:
|
Completed |
Nombre del estudio: Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Condición: Secondary Hyperparathyroidism Fecha: 2015-01-11 Intervenciones: Drug: Combination Cinacalcet with Vitamin D analogue Depending on the iPTH level and the serum calcium l |
Completed |
Nombre del estudio: LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients Condición: Secondary Hyperparathyroidism Fecha: 2010-07-02 Intervenciones: Drug: LEO 27847 First in patient |
Completed |
Nombre del estudio: Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Condición: Secondary Hyperparathyroidism Fecha: 2010-04-19 Intervenciones:
|
Completed |
Nombre del estudio: A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism Condición: Secondary Hyperparathyroidism Fecha: 2012-07-25 Intervenciones: Drug: DP001 DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks |
Recruiting |
Nombre del estudio: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) Condición: Hyperparathyroidism, Secondary Fecha: 2014-06-27 Intervenciones:
|
Terminated |
Nombre del estudio: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism Condición: Secondary Hyperparathyroidism Fecha: 2012-04-05 Intervenciones: Drug: Etelcalcetide Administered as an intravenous bolus three times a week at the end of each hemodialy |
Completed |
Nombre del estudio: ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Condición: Secondary Hyperparathyroidism Fecha: 2005-08-24 Intervenciones:
|
Completed |
Nombre del estudio: Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Condición: Secondary Hyperparathyroidism Due to Renal Causes Fecha: 2013-08-28 Intervenciones:
|